BGLAP and rheumatoid arthritis: Vis et al. [22] described a decrease in the bone resorption marker (i.e., cross-linked C-terminal telopeptides of type I collagen (ICTP)), and an increase in the bone formation markers (i.e., PINP and osteocalcin (OC)) after six weeks of treatment with infliximab in RA patients.